Status:
COMPLETED
LVEF Prediction During ACS Using AI Algorithm Applied on Coronary Angiogram Videos
Lead Sponsor:
Montreal Heart Institute
Collaborating Sponsors:
Ottawa Heart Institute Research Corporation
Conditions:
Acute Coronary Syndrome
Left Ventricular Dysfunction
Eligibility:
All Genders
18+ years
Brief Summary
Left ventricular ejection fraction (LVEF) is one of the strongest predictors of mortality and morbidity in patients with acute coronary syndrome (ACS). Transthoracic echocardiography (TTE) remains the...
Eligibility Criteria
Inclusion
- Informed consent signed by the participant
- Acute coronary syndrome
- Creatinine clearance ≥30 ml/min/m2 according to MDRD
Exclusion
- Creatinine clearance \<30 ml/min/m2 according to MDRD
- No indication to perform TTE in the 7 days following coronary angiogram
- Right bundle branch block
- Suspected or confirmed left ventricular thrombus
- Suspected or confirmed aortic dissection
- Ventriculography not feasible
- No left coronary system angiogram
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 29 2024
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05317286
Start Date
June 1 2022
End Date
February 29 2024
Last Update
March 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert Avram
Montreal, Quebec, Canada, H1T1C8